Glenmede Trust CO Na Viking Therapeutics, Inc. Transaction History

Glenmede Trust CO Na

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $143,165 - $242,284	-3,021 Reduced 42.86%	4,028 $213,000
Q1 2024 May 15, 2024	BUY	$17.4 - $94.5 $122,652 - $666,130	7,049 New	7,049 $578,000
Q1 2023 May 15, 2023	SELL	$8.08 - $17.33 $2,068 - $4,436	-256 Reduced 1.01%	25,033 $416,000
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $68,786 - $237,716	25,289 New	25,289 $237,000

476

63.4M

5.76M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.5B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.